Other drugs, such as LBH589 or CRLX101 also exhibit antitumor effects by reducing HIF-1α and VEGF expression [107,108], while OKN-007, a novel anti-glioma nitrone-based agent, can also be synergically to TMZ inducing a significant decrease in tumor progression by targeting TGF-β1 pathway-promoting angiogenesis [111]. This evidence concerns the gene TGFB1 and central nervous system cancer.